These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25696865)

  • 1. A practical approach to relapsed multiple myeloma.
    Mikhael JR
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):262-7. PubMed ID: 25696865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Relapsed/Refractory Multiple Myeloma.
    Neri P; Bahlis NJ; Paba-Prada C; Richardson P
    Cancer Treat Res; 2016; 169():169-194. PubMed ID: 27696263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple myeloma: from front-line to relapsed therapies.
    Moreau P; Touzeau C
    Am Soc Clin Oncol Educ Book; 2015; ():e504-11. PubMed ID: 25993216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pomalidomide for multiple myeloma.
    Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
    Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives.
    Jakubowiak A
    Semin Hematol; 2012 Jul; 49 Suppl 1():S16-32. PubMed ID: 22727389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The next generation of novel therapies for the management of relapsed multiple myeloma.
    Gonsalves WI; Milani P; Derudas D; Buadi FK
    Future Oncol; 2017 Jan; 13(1):63-75. PubMed ID: 27513456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel agents for relapsed and/or refractory multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy for relapsed multiple myeloma.
    Aljama MA; Sidiqi MH; Dingli D
    Panminerva Med; 2018 Dec; 60(4):174-184. PubMed ID: 30303355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
    Highsmith KN; Chen SE; Horowitz S
    Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options.
    Ramasamy K; Gay F; Weisel K; Zweegman S; Mateos MV; Richardson P
    Blood Rev; 2021 Sep; 49():100808. PubMed ID: 33863601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
    Richardson PG; Laubach J; Mitsiades C; Schlossman RL; Doss D; Colson K; McKenney ML; Noonan K; Warren DL; Ghobrial IM; Munshi NC; Anderson K
    Oncology (Williston Park); 2010 Mar; 24(3 Suppl 2):22-9. PubMed ID: 20518367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
    van de Donk NW; Lokhorst HM; Dimopoulos M; Cavo M; Morgan G; Einsele H; Kropff M; Schey S; Avet-Loiseau H; Ludwig H; Goldschmidt H; Sonneveld P; Johnsen HE; Bladé J; San-Miguel JF; Palumbo A
    Cancer Treat Rev; 2011 Jun; 37(4):266-83. PubMed ID: 20863623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pomalidomide in the treatment of relapsed multiple myeloma.
    Forsberg PA; Mark TM
    Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics of patients with relapsed multiple myeloma.
    Dimopoulos MA; Terpos E; Niesvizky R; Palumbo A
    Cancer Treat Rev; 2015 Dec; 41(10):827-35. PubMed ID: 26296679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.
    Richardson PG; Harvey RD; Laubach JP; Moreau P; Lonial S; San-Miguel JF
    Expert Rev Clin Pharmacol; 2016; 9(1):35-48. PubMed ID: 26503877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide in multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [State of the art treatment of progressive or refractory multiple myeloma].
    Schmidt-Wolf IG; Straka C; Scheid C; Einsele H; Goldschmidt H; Engelhardt M
    Dtsch Med Wochenschr; 2014 Oct; 139(41):2091-5. PubMed ID: 25268212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of relapsed and refractory multiple myeloma.
    Moehler T; Goldschmidt H
    Recent Results Cancer Res; 2011; 183():239-71. PubMed ID: 21509688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The treatment of relapsed or refractory multiple myeloma].
    Tsurumi H
    Nihon Rinsho; 2015 Jan; 73(1):114-8. PubMed ID: 25626315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.